Watch Bloomberg Businessweek Daily LIVE every day on YouTube: http://bit.ly/3vTiACF.

The fight over the future of Hollywood just got nastier.

Paramount Skydance Corp. launched a hostile takeover bid for Warner Bros. Discovery Inc. at $30 a share in cash on Monday, just days after the company agreed to a deal with Netflix Inc. The offer values Warner Bros. at $108.4 billion, including debt.

The bid compares with Netflix’s offer of $27.75 in cash and stock, for an enterprise value of about $82.7 billion including debt. Paramount’s offer is for all of Warner Bros., while Netflix is interested only in the Hollywood studios, HBO and the streaming business.

Warner Bros. investors “deserve an opportunity to consider our superior all-cash offer for their shares in the entire company,” Paramount Chief Executive Officer David Ellison said in a statement.

The battle between Netflix and Paramount stands to reshape the entertainment industry regardless of who wins. With Warner Bros. films and TV shows, Netflix would wield tremendous new power over the content offered to online audiences. Paramount aims to marry two legacy Hollywood studios to counter the influence of Netflix, Walt Disney Co. and Amazon.com Inc.

Both bids raise significant antitrust concerns, underscored by multibillion-dollar breakup fees the parties have offered, and both companies have been laying the groundwork to win over the White House.

Today's show features:

• Bloomberg News Media and Entertainment Editor Felix Gillette and Bloomberg News Intelligence Senior Media Analyst Geetha Ranganathan on Paramount’s $108 billion hostile takeover bid for Warner Bros. Discovery
• Kevin Gordon, Head of Macro Research and Strategy for the Schwab Center for Financial Research, on inflation, labor and AI investing trends
• Bloomberg News Chief Wall Street Correspondent Sridhar Natarajan and US Insurance Reporter Alex Rajbhandari on the ripple effects of JPMorgan hiring Todd Combs away from Berkshire Hathaway
• Gracelin Baskaran, Director of Critical Minerals Security Program at Center for Strategic and International Studies, on the US and Democratic Republic of Congo signing a partnership to create a strategic reserve of critical mineral assets and current state of play in the sector

See omnystudio.com/listener for privacy information.

Compass Pathways is a mental health care company developing new treatments for people who haven’t responded to existing medications and continue to struggle with their mental health. The company was the first to report successful Phase 3 clinical trial results for a psychedelic treatment, known as COMP360 psilocybin, for treatment-resistant depression (TRD) and is positioned to potentially be the first to receive regulatory approval and bring a psychedelic-based medicine to market.

Kabir Nath, the CEO of Compass Pathways, details his company's path building a scalable, safe, and accessible psychedelic care system and model. Kabir speaks with Carol Massar and Alexis Christoforous on Bloomberg Businessweek Daily.

See omnystudio.com/listener for privacy information.

Featuring some of our favorite conversations of the week from our daily radio show "Bloomberg Businessweek Daily."
Hosted by Carol Massar and Tim Stenovec

Hear the show live at 2PM ET on WBBR 1130 AM New York, Bloomberg 92.9 FM Boston, WDCH 99.1 FM in Washington D.C. Metro, Sirius/XM channel 121, on the Bloomberg Business App, Radio.com, the iHeartRadio app and at Bloomberg.com/audio.

You can also watch Bloomberg Businessweek on YouTube - just search for Bloomberg Global News.
Like us at Bloomberg Radio on Facebook and follow us on Twitter @carolmassar @timsteno and @BW

See omnystudio.com/listener for privacy information.